Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial AgentsLeslie W. Tari, John Finn, Amanda Castellano et al.|PLoS ONE|2013Cited by 104
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: Development of inhibitors with broad spectrum, Gram-negative antibacterial activityMicheal Trzoss, Leslie W. Tari, Felice C. Lightstone et al.|Bioorganic & Medicinal Chemistry Letters|2012Cited by 81
Distinguishing On-Target versus Off-Target Activity in Early Antibacterial Drug Discovery Using a Macromolecular Synthesis AssayMark L. Cunningham, Karen Joy Shaw, Kirk Nelson et al.|SLAS DISCOVERY|2013Cited by 39
Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitorsLeslie W. Tari, Ronald V. Swanson, Isaac Hoffman et al.|Bioorganic & Medicinal Chemistry Letters|2006Cited by 37
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L. Hudkins, Daniel C. Bensen, Samhita Iyer et al.|Journal of Medicinal Chemistry|2024Cited by 28